Elite Pharmaceuticals (ELTP) Stock Analysis & Winston Score

Elite Pharmaceuticals is a small drug company that makes generic prescription medicines. It focuses on controlled-release and abuse-deterrent formulations, meaning pills designed to release medication slowly or to be harder to misuse. Its main products include generic versions of pain and attention-deficit medications, sold primarily to wholesalers and pharmacies across the United States. The company earns money by manufacturing and selling these generic drugs, and it also licenses its drug-delivery technology to other pharmaceutical companies for additional revenue. It operates entirely in the U.S. and, with a market cap around $400 million, is considered a micro-cap business. Its proprietary controlled-release technology gives it a degree of differentiation in an otherwise highly competitive generic drug market. The key growth driver is expanding its product pipeline and securing new licensing deals, but the main risk is pricing pressure in generics, where competition from other manufacturers can quickly erode profit margins.